Fractyl Health, Inc. income statement GUTS

In fiscal 2025, which ended Dec 31, 2025, Fractyl Health, Inc. reported revenue of $0, down 100.0% from the year before. It recorded a net loss of $141.0 million. Diluted earnings per share were -$1.86.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Revenue
0
-100.0%
0
Cost of revenue
0
-100.0%
0
Gross profit
0
-100.0%
0
Research and development
75
+5.8%
70
Selling, general and administrative
22
-3.6%
23
Operating expenses
97
+3.5%
94
Operating income
-97
-3.5%
-94
Income tax
0
0
Net income
-141
-105.2%
-69
Basic EPS
-1.86
-14.8%
-1.62
Diluted EPS
-1.86
-14.8%
-1.62
Weighted average shares, basic
76
+74.1%
44
Weighted average shares, diluted
76
+74.1%
44
Other measures
Depreciation and amortization
1
+66.8%
1
EBITDA
-96
-3.1%
-93
Margins
Gross margin
—
46.24%
Operating margin
—
-100,570.97%
Profit margin
—
-73,864.52%
EBITDA margin
—
-99,843.01%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
GUTS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Burlington, MA
SEC filer status
, Emerging growth company
SEC CIK
1572616
Former names
Fractyl Laboratories Inc. (until Mar 19, 2020)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.